Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hippo Holdings (HIPO) Other Accumulated Expenses (2020 - 2026)

Hippo Holdings filings provide 7 years of Other Accumulated Expenses readings, the most recent being $482.6 million for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 20.41% to $482.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $482.6 million, a 20.41% increase, with the full-year FY2025 number at $420.4 million, up 20.11% from a year prior.
  • Other Accumulated Expenses hit $482.6 million in Q1 2026 for Hippo Holdings, up from $420.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $482.6 million in Q1 2026 to a low of $268.8 million in Q2 2022.
  • Median Other Accumulated Expenses over the past 5 years was $350.0 million (2024), compared with a mean of $352.0 million.
  • Biggest five-year swings in Other Accumulated Expenses: surged 68.2% in 2022 and later dropped 5.63% in 2024.
  • Hippo Holdings' Other Accumulated Expenses stood at $293.8 million in 2022, then rose by 9.77% to $322.5 million in 2023, then grew by 8.53% to $350.0 million in 2024, then increased by 20.11% to $420.4 million in 2025, then grew by 14.8% to $482.6 million in 2026.
  • The last three reported values for Other Accumulated Expenses were $482.6 million (Q1 2026), $420.4 million (Q4 2025), and $384.4 million (Q3 2025) per Business Quant data.